Platinum-based chemotherapy combination

This page covers all Platinum-based chemotherapy combination drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting DNA (oxaliplatin); thymidylate synthase (capecitabine/5-FU).

Targets

DNA (oxaliplatin); thymidylate synthase (capecitabine/5-FU)

Marketed (1)

• oxaliplatin plus capecitabine · LiNing · Oncology
  Oxaliplatin and capecitabine work together as a chemotherapy combination where oxaliplatin cross-links DNA to prevent replication while capecitabine is converted to fluorouracil to inhibit thymidylate synthase and disrupt nucleotide synthesis.

Phase 3 pipeline (1)

• platinum-based dual-agent chemotherapy · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Oncology
  Platinum-based dual-agent chemotherapy uses two platinum compounds or a platinum compound combined with another cytotoxic agent to create synergistic DNA damage and cell death in cancer cells.